November 2026 Trial Snapshot
💻
Best viewed on desktop
The Prostate Cancer trial snapshot includes an interactive map and data tables that work best on a larger screen.
Read the Prostate Cancer research guide →Active sponsors
Trials
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
Hypofractionated Radiotherapy With Magnetic Resonance Imaging-Guided Focal Boost and Pelvic Irradiation in High-Risk Prostate Cancer
Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC)
AXT-1003 Combination With Enzalutamide in Participants With mCRPC
RYZ711 Diagnostic Platform Study
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
Showing trials with activity in the past 30 days. See the full Prostate Cancer research landscape →
Recently completed · awaiting results
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer
Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Condition guide
Prostate Cancer — the full picture
Research landscape, trial types, and what eligibility typically looks like — written for patients but useful for everyone.
Monthly digest
Get this brief every month
We’ll email you the Prostate Cancerbrief as soon as it’s published — no login required.
Coming soon